About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
Twitter List
Legislative Tracking Tools
Monthly Archives: May 2009
Weekly Roundup – 5/29/09
Oh gosh. The pollen count is off the charts. Summer storms are overanxious and overabundant. The first tropical depression has appeared off the Atlantic just prior to the official beginning of the Hurricane Season. A diabetic is ascending to the … Continue reading
Posted in Weekly Roundup
Comments Off on Weekly Roundup – 5/29/09
FDA’s Non-Guidance on Relating Risk Information is FDA’s Loss – Industry’s Opportunity
This week, the FDA issued a Draft Guidance on Presenting Risk Information in Prescription Drug and Medical Device Promotion. It is more accurately referred to as a Non-Guidance. According to FDA's DDMAC, the Internet has not really taken hold yet. … Continue reading
Posted in New and Social Media
Comments Off on FDA’s Non-Guidance on Relating Risk Information is FDA’s Loss – Industry’s Opportunity
Warning Letter Quarterly Update, Last Quarter 2008, First Quarter 2009, Part 2
Ok, last week, I ran a posting that profiled the rate of Warning and Untitled Letter rate from FDA's DDMAC, this week, let's look at the substance and see what, if any, lessons there are to be learned from DDMAC … Continue reading
Posted in Warning Letters
Comments Off on Warning Letter Quarterly Update, Last Quarter 2008, First Quarter 2009, Part 2
New Pharma in New Media – GSK Launches New Blog – Teva a New YouTube Channel
Slowly, but surely, the migration of pharmaceutical companies into new media is occurring. Given it has b een a glacial pace, and far behind other industries. FDA's DDMAC says one thing and does another when it comes to regulating the … Continue reading
Posted in New and Social Media
2 Comments
Margaret Hamburg Gets Unanimous Senate Approval
It could be the end of an era. For many years, the FDA has lacked decisive leadership and strategic vision. The agency, which was once the gold-standard of regulatory agencies, has seen that gold tarnish overtime while it … Continue reading
Posted in FDA Image
Comments Off on Margaret Hamburg Gets Unanimous Senate Approval